Scientists and drug developers share their views on whether semaglutide and similar drugs could work as longevity medicines. Their verdict so far is that it's too early to say.
Recap by typeshit. Full story at The Scientist.
The Scientist weighs whether GLP-1 drugs could lengthen life and finds the answer still unsettled. Tap through for where the research stands.
The review covers 47 peptides from meat, leather and seafood waste and cites a 12-trial meta-analysis showing a systolic drop of about 5 mmHg, credited to the authors.
Researchers think orexin drugs could expand into ADHD and fatigue the way GLP-1s grew past diabetes. Alkermes reported early ADHD results in 50 adults.
Researchers report in Amino Acids that the peptide blocks HMGA2 at the IL6 promoter in a cell model. The authors note the work is cell culture only, far from any human use.
Records from about 4,900 German practices show over half of patients stayed below 10 mg in their first six months, with 5 mg the most common dose.
In over 61,000 matched patients, coded lymphedema hit 0.88% of GLP-1 users versus 2.58% of non-users. Authors call it hypothesis-generating, not proof.
Loading…